RESIQUIMOD Struktur

RESIQUIMOD

Bezeichnung:RESIQUIMOD

CAS-Nr144875-48-9

Englisch Name:RESIQUIMOD

CBNumberCB62446527

SummenformelC17H22N4O2

Molgewicht314.38

MOL-Datei144875-48-9.mol

RESIQUIMOD physikalisch-chemischer Eigenschaften

Schmelzpunkt	190-193°
Siedepunkt	553.6±50.0 °C(Predicted)
Dichte	1.28
storage temp.	-20°C
Löslichkeit	DMSO: soluble10mg/mL, clear (warmed to 60 °C)
pka	14.63±0.29(Predicted)
Aggregatzustand	powder
Farbe	white to tan
maximale Wellenlänge (λmax)	325nm(lit.)
Merck	14,8151
Stabilität	Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months.
InChIKey	BXNMTOQRYBFHNZ-UHFFFAOYSA-N

Sicherheit

WGK Germany	3
RTECS-Nr.	NJ5911320
HS Code	2933998090

Gefahreninformationscode (GHS)

RESIQUIMOD Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Resiquimod (CAS 144875-48-9) is a Toll-like receptor 7/8 agonist.1 May be used as an immune adjuvant in cancer vaccines.2 Resiquimod-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.3 Topical treatment of wild-type mice induces systemic autoimmune disease which may be used as a model of systemic Lupus erythematosus.4? It displayed potent antiviral activity (EC50 = 23.5 nM) in a murine norovirus replicon model.5
Verwenden
Resiquimod is an imidazoquinoline derivative that acts as an immune response modifier. Resiquimod shows antitumor and antiviral activity and is used in the treatment of skin lesions such as herpes simplex virus. Resiquimod is a toll-like receptor 9 (TLR7) agonist.
Verwenden
Resiquimod has been used in the stimulation of bone marrow-derived dendritic cells (BMDCs) stimulation( and B cells. It has also been used as a ligand for toll-like receptors (TLR7) in malignant melanoma cell line B16F10.
Definition
ChEBI: Resiquimod is an imidazoquinoline.
Biochem/physiol Actions
Resiquimod belongs to the class of imidazoquinolinamines compounds with immunomodulatory effects. Resiquimod increases the levels of cytokines such as TNF-α, IL-6 and IFN-α.
Lager
Store at +4°C
Einzelnachweise
1) Jurk et al. (2002), Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848; Nat. Immunol., 3 499 2) Sabado et al. (2015), Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma; Cancer Immunol. Res., 3 278 3) Ilyinskii et al. (2014), Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release; Vaccine, 32 2882 4) Yokogawa et al. (2014), Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erthematosus; Arthritis Rheumatol., 66 694 5) Tuipulotu et al. (2018), TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation; Antimicrob. Agents Chemother., 62 e02417

RESIQUIMOD Upstream-Materialien And Downstream Produkte

RESIQUIMOD Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

144875-48-9, RESIQUIMOD Verwandte Suche:

Send Inquriy